Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
0.61 CAD
6.46 M CAD
31.59 M CAD
6.98 M
About BIOSYENT INC
Sector
CEO
René C. Goehrum
Headquarters
Mississauga
Website
Founded
1947
FIGI
BBG000BZ3YM7
BioSyent, Inc. is a specialty pharmaceutical company, which engages in the development of pharmaceutical and healthcare products. Its products include Cathejell Jelly, FeraMAX Pd Therapeutic 150, FeraMAX Pd Powder 15, Proktis-M, RepaGyn, and cTIBELLA. The company was founded on April 28, 1947 and is headquartered in Mississauga, Canada.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of RX is 11.51 CAD — it has decreased by −3.47% in the past 24 hours. Watch BIOSYENT INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on TSXV exchange BIOSYENT INC stocks are traded under the ticker RX.
RX stock has risen by 1.18% compared to the previous week, the month change is a −0.27% fall, over the last year BIOSYENT INC has showed a 33.22% increase.
We've gathered analysts' opinions on BIOSYENT INC future price: according to them, RX price has a max estimate of 11.75 CAD and a min estimate of 11.75 CAD. Watch RX chart and read a more detailed BIOSYENT INC stock forecast: see what analysts think of BIOSYENT INC and suggest that you do with its stocks.
RX stock is 3.60% volatile and has beta coefficient of −0.32. Track BIOSYENT INC stock price on the chart and check out the list of the most volatile stocks — is BIOSYENT INC there?
Today BIOSYENT INC has the market capitalization of 133.56 M, it has decreased by −0.48% over the last week.
Yes, you can track BIOSYENT INC financials in yearly and quarterly reports right on TradingView.
BIOSYENT INC is going to release the next earnings report on Mar 19, 2025. Keep track of upcoming events with our Earnings Calendar.
RX earnings for the last quarter are 0.20 CAD per share, whereas the estimation was 0.14 CAD resulting in a 42.86% surprise. The estimated earnings for the next quarter are 0.15 CAD per share. See more details about BIOSYENT INC earnings.
BIOSYENT INC revenue for the last quarter amounts to 9.56 M CAD, despite the estimated figure of 9.00 M CAD. In the next quarter, revenue is expected to reach 9.10 M CAD.
RX net income for the last quarter is 2.31 M CAD, while the quarter before that showed 1.58 M CAD of net income which accounts for 46.04% change. Track more BIOSYENT INC financial stats to get the full picture.
Yes, RX dividends are paid quarterly. The last dividend per share was 0.05 CAD. As of today, Dividend Yield (TTM)% is 1.52%. Tracking BIOSYENT INC dividends might help you take more informed decisions.
BIOSYENT INC dividend yield was 1.79% in 2023, and payout ratio reached 30.52%. The year before the numbers were 1.14% and 18.03% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. BIOSYENT INC EBITDA is 8.69 M CAD, and current EBITDA margin is 25.29%. See more stats in BIOSYENT INC financial statements.
Like other stocks, RX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade BIOSYENT INC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So BIOSYENT INC technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating BIOSYENT INC stock shows the strong buy signal. See more of BIOSYENT INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.